cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Nurul Hidayah
Contact Email
sccrlaboratory@gmail.com
Phone
+628164251646
Journal Mail Official
dr.agungptr@gmail.com
Editorial Address
Jalan Kol.R.W Sugiarto, Nongkosawit, Gunungpati, Kota Semarang, 50223, Indonesia
Location
Kota semarang,
Jawa tengah
INDONESIA
International Journal of Cell and Biomedical Science
Published by Stem Cell and Cancer Research Indonesia
ISSN : -     EISSN : 28296621     DOI : https://doi.org/10.59278/
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology
International Journal of Cell and Biomedical Science, formerly CBS Int. Journal is an open-access, peer-reviewed journal published by Stem Cell and Cancer Research (SCCR), Indonesia. The journal publishes papers describing original findings and reviews articles in all aspects of cell, molecular biology, and biomedical research. Received manuscripts are accepted for publication only after rigorously being reviewed by independent experts in the respective fields determining the originality, validity, and conclusions.
Arjuna Subject : Biokimia, Genetika dan Biologi Molekuler - Biokimia, Genetika dan Biologi Molekuler (Lain-Lain)
Articles 55 Documents
 2   3   4   5   6 
Surface Marker Expression and Morphological Alterations in Umbilical Cord-Derived MSCs Over Passages 4 to 9: A Flow Cytometry and Microscopic Analysis Prawitasari, Salindri; Ayu, Dian Respati; Irawan, Risky Chandra Satria; Prabowo, Adam
International Journal of Cell and Biomedical Science Vol 3 No 9 (2024)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v3i9.51

Abstract

Background : Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are promising candidates for regenerative medicine due to their high proliferative capacity, multilineage differentiation potential, and low immunogenicity. However, prolonged in vitro expansion may lead to phenotypic drift and morphological changes that could impact their therapeutic efficacy. This study aimed to evaluate the expression of mesenchymal surface markers (CD73, CD90, CD105) and morphological characteristics of UC-MSCs from passage 4 (P4) to passage 9 (P9). Methods: Flow cytometry was employed using the BD Stemflow™ Human MSC Analysis Kit to quantify the expression of both positive and negative surface markers, while morphological assessments were performed via phase-contrast microscopy. Results : The results revealed that UC-MSCs maintained high expression levels of CD73, CD90, and CD105 across all passages, although a slight decline was observed in later passages. Morphological analysis indicated a transition from spindle-shaped, fibroblast-like cells at early passages to more enlarged and flattened cells with signs of senescence at higher passages. Conclusions : These findings suggest that although UC-MSCs retain their phenotypic identity up to P9, subtle morphological and marker expression changes may occur, underscoring the importance of passage selection in therapeutic applications. This study contributes to the optimization of UC-MSC culture protocols for standardized and effective clinical use.
In Vitro Transcription as a Strategy to Enhance Mesenchymal Stem Cell Secretome for Therapeutic Use: An Overview Nugraha, Dendi Krisna; Falah, Ariq
International Journal of Cell and Biomedical Science Vol 3 No 9 (2024)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v3i9.61

Abstract

Mesenchymal stem cells (MSCs) have become a cornerstone of regenerative medicine owing to their capacity to secrete a diverse array of bioactive molecules, collectively termed the secretome. The MSC secretome exerts profound immunomodulatory, anti-inflammatory, and trophic effects that underpin much of the therapeutic efficacy observed in MSC-based interventions. Nevertheless, variability in the secretory profile across donors, tissue sources, and culture conditions continues to limit the reproducibility and potency of MSC-derived therapies. Recent advancements in in vitro transcription (IVT) mRNA technology have emerged as a robust and transient platform for the reprogramming of mesenchymal stem cells (MSCs) without the need for genomic integration. Through the use of IVT-mRNA-mediated expression of selected cytokines, growth factors, or homing receptors, MSCs can be endowed with enhanced anti-inflammatory and regenerative capabilities while preserving their native phenotype and viability. This review summarizes current IVT-mRNA–based strategies for engineering the MSC secretome, with an emphasis on augmenting anti-inflammatory cytokines (e.g., IL-10, TSG-6) and growth factors (e.g., VEGF, HGF, FGF2). The review also examines how IVT-mRNA redefines the cellular secretory landscape, outlines key considerations in IVT-mRNA design and optimization, and discusses translational implications for both cell-based and cell-free therapeutic applications. Finally, it underscores persistent challenges, including transient transgene expression, innate immune activation, and delivery inefficiency, and contemplates future prospects for integrating IVT-mRNA technology with advanced biomaterials, cellular priming methodologies, and multifactorial modulation to achieve consistent and potent therapeutic secretomes.
Hypoxia-Induced Modulation of OCT-4, SOX-2, NANOG, and KLF-4 Expression in Mesenchymal Stem Cells Irawan, Risky Chandra Satria; Hidayah, Nurul; Wilaksono, Bhirau
International Journal of Cell and Biomedical Science Vol 3 No 9 (2024)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v3i9.62

Abstract

Background: Mesenchymal stem cells (MSCs) possess remarkable regenerative and immunomodulatory capabilities, largely attributed to their intrinsic stemness properties regulated by transcription factors such as OCT-4, SOX-2, NANOG, and KLF-4. However, in vitro culture under normoxia often leads to stemness decline. Hypoxic preconditioning has been proposed to preserve stemness, though the optimal duration of exposure remains unclear. This study aimed to evaluate the time-dependent effects of hypoxia on the expression of core stemness-related transcription factors in human umbilical cord Wharton’s jelly-derived MSCs. Methods: MSCs (passage 5) obtained from the Stem Cell and Cancer Research (SCCR) Laboratory were cultured under hypoxia (5% O₂) for 0, 4, 6, 10, 12, and 24 hours. Gene expression of OCT-4, SOX-2, NANOG, and KLF-4 was quantified by qRT-PCR using GAPDH as a reference. Morphological changes were observed via phase-contrast microscopy. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test. Results: Hypoxic exposure induced a significant, time-dependent upregulation of OCT-4, SOX-2, and NANOG, with peak expression at 12 hours (approximately 13-, 7-, and 5-fold increases, respectively; p < 0.05). KLF-4 expression showed a modest elevation but was not statistically significant. Prolonged hypoxia (24 hours) resulted in a marked decline in all gene expressions toward baseline levels, accompanied by cell rounding and detachment. These findings indicate that short-term hypoxia enhances MSC stemness, while extended exposure triggers stress-related responses. Conclusion: Controlled short-term hypoxia (approximately 12 hours at 5% O₂) optimally enhances MSC stemness gene expression without compromising morphology or viability. This duration represents an effective preconditioning window for maintaining MSC multipotency and may improve the consistency and therapeutic efficacy of MSC-based applications.
hUC-MSCs Therapy with EVs Booster Improves Recovery in Stage 2 Chronic Kidney Disease with Hypercholesterolemia : a case report Jutadi; Ayu, Dian Respati; Cahyani, Dini; Arda, Adzani Gaisani; Anggoro, Naufal Sebastian
International Journal of Cell and Biomedical Science Vol 3 No 9 (2024)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v3i9.63

Abstract

Hypercholesterolemia is a common metabolic comorbidity that accelerates the progression of chronic kidney disease (CKD). Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) and their secretome, which consist of extracellular vecicles (EVs) and soluble bioactive molecules, have shown potential in modulating inflammation and metabolism. This case report describes significant improvement in serum lipid profile following hUC-MSC and secretome therapy in a patient with stage 2 CKD and hypercholesterolemia. A male patient with CKD stage 2 received two intravenous cycles of hUC-MSC and secretome therapy administered seven months apart. Serial evaluations demonstrated a progressive decline in total cholesterol from 294 mg/dL at baseline to 286 mg/dL after the first treatment and 225 mg/dL after the second. LDL cholesterol decreased from 188 mg/dL to 140 mg/dL, with a mild rebound to 175 mg/dL. HDL cholesterol, initially elevated at 214 mg/dL, showed a modest increase to 220 mg/dL after the first treatment, followed by normalization to 175 mg/dL. Triglyceride levels remained within the normal range (44–51 mg/dL) throughout the observation period. The marked improvement in lipid parameters suggests that hUC-MSC and secretome therapy may exert systemic metabolic regulation via anti-inflammatory, antioxidative, and hepatoprotective mechanisms. hUC-MSC and secretome administration demonstrated potential benefits in lipid homeostasis in a patient with CKD and hypercholesterolemia. These findings support the role of MSC-derived secretome as a promising adjunctive therapeutic approach. Larger controlled trials are warranted to confirm these outcomes and elucidate underlying mechanisms.
Time-Dependent Simulation Identifies Critical Hour Phase of Intestinal Acute Injury in Sepsis Mouse Model Istanti, Yusrina; Anggoro, Naufal Sebastian; Husain, Sofian Azalia; Azzahara, Salma Yasmine
International Journal of Cell and Biomedical Science Vol 3 No 9 (2024)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v3i9.64

Abstract

Background: Understanding the dynamic process of intestinal injury and repair during sepsis is essential for identifying optimal therapeutic windows. This study aimed to determine the critical time phase of intestinal acute injury by analyzing histological changes over a 24-hour period in a sepsis mouse model. Methods: Mice were divided into four groups—Control, 9 h, 12 h, and 24 h—and intestinal tissue samples were assessed using the Chiu histological scoring system. A time-dependent simulation was conducted to evaluate average changes in tissue damage and to identify key transition points between injury and recovery phases. Statistical analysis was performed using one-way ANOVA followed by post hoc comparisons to determine significant differences among time points. Results: The simulation demonstrated a marked increase in intestinal damage between 9 h and 12 h, followed by partial recovery at 24 h. Statistical analysis revealed a significant difference (p < 0.05) corresponding to this shift. These findings suggest that peak tissue injury occurs around 12 hours post-sepsis induction, preceding the onset of repair mechanisms. Conclusion: The study provides quantitative insight into the temporal progression of intestinal injury in sepsis, identifying the 12–24 hour period as a critical therapeutic window for potential interventions.
Bax/Bcl-2 Ratio as the Golden Marker of Apoptosis: Molecular Mechanisms and Regulatory Pathways Putri, Ghea Farmaning Thias; Nurfatihah Z, Zahara
International Journal of Cell and Biomedical Science Vol 4 No 10 (2025)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v4i10.65

Abstract

Apoptosis is an essential biological mechanism responsible for maintaining tissue homeostasis by removing unnecessary or damaged cells. Among the key molecular regulators, the interplay between the pro-apoptotic protein Bax and the anti-apoptotic protein Bcl-2 determines cellular fate. The Bax/Bcl-2 ratio has been recognized as the “golden marker” of apoptosis, representing the fine equilibrium between survival and death signaling pathways within cells. This review aims to provide an updated overview of recent advances in understanding the molecular mechanisms and regulatory networks that control the Bax/Bcl-2 ratio and its significance as a diagnostic and therapeutic biomarker. Relevant studies were systematically identified from PubMed, Scopus, ScienceDirect, and Google Scholar, focusing on publications from 2020 to 2025. Current evidence suggests that the Bax/Bcl-2 ratio is influenced by transcriptional regulation involving p53, NF-κB, and Akt/PI3K pathways, as well as by post-translational modifications such as phosphorylation and ubiquitination that govern mitochondrial membrane permeabilization. Clinically, alterations in this ratio correlate with disease progression, therapeutic response, and prognosis in cancer, neurodegenerative, and renal disorders. Targeting this ratio through modulation of upstream regulators or BH3 mimetics offers promising therapeutic potential. In conclusion, a deeper understanding of the Bax/Bcl-2 ratio provides crucial perspectives for advancing diagnostic innovation and developing targeted therapies for apoptosis-related diseases.
Human-Umbilical Cord-Mesenchymal Stem Cells (hUC-MCSs) Therapy with Extravesicles (EVs) Booster Improves Recovery in Type 2 Diabetes Mellitus with Cardiovascular Disease Nugraha, Dendi Krisna; Jutadi; Anggoro, Naufal Sebastian; Sari, Fikriya Novita; Ardani, Yanuar
International Journal of Cell and Biomedical Science Vol 4 No 10 (2025)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v4i10.66

Abstract

Background: Type 2 diabetes (T2DM) is a chronic metabolic disorder characterized by insulin resistance and β-cell dysfunction, leading to persistent hyperglycemia and complications. Studies have explored mesenchymal stem cell (MSC)-based therapies and their extracellular vesicles (EVs) as novel approaches for metabolic regulation and tissue repair. Case: A 43-year-old male patient exhibited symptoms including excessive thirst and hunger, frequent urination, fatigue, and intermittent blurry vision. He had type 2 diabetes and recently worsened symptoms. The obese patient had elevated blood glucose, HbA1c, triglycerides, and uric acid. He received umbilical cord-derived mesenchymal stem cells (161,6 × 106 cells), followed by seven intramuscular EV injections (1.5 cc each), along with diet and antioxidant supplements. Results: Three months after the conclusion of treatment, laboratory test showed significant improvement, with fasting glucose levels measuring at 91 mg/dL, HbA1c levels at 5,1%, triglyceride levels at 151 mg/dL, uric acid levels at 4,9 mg/dL, and an erythrocyte sedimentation rate of 12 mm/hr. The clinical symptoms such as nocturia, fatigue, and neuropathic pain, demonstrated a substantial improvement, as well as led to the resolution of skin xerosis and heel fissures. Conclusion: This case suggests that combined UC-MSC and EV therapy, complemented by lifestyle modification, may contribute to metabolic stabilization and symptomatic relief in T2DM patients.
Effects of Extracellular pH Modulation on HIF-1α, c-Myc, and FOXO1 Expression in Colorectal Cancer Cells Ibrahim, Sugeng; Putri Rifai, Fauziah Novita; Arda, Adzani Gaisani
International Journal of Cell and Biomedical Science Vol 4 No 10 (2025)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v4i10.67

Abstract

Background: The tumor microenvironment (TME) of colorectal cancer (CRC) is characterized by an inverted pH gradient, with acidic extracellular and alkaline intracellular conditions that promote tumor progression and metabolic reprogramming. This altered pH landscape regulates key transcriptional drivers of glycolysis and proliferation, including hypoxia-inducible factor-1 alpha (HIF-1α), c-Myc, and the tumor suppressor Forkhead Box Protein O1 (FOXO1). Understanding how extracellular pH influences these regulators may provide new insights for pH-targeted cancer therapy. Methods: Human colorectal carcinoma HCT116 cells were cultured for 24 hours under six extracellular pH conditions (5.5–9.2). The expression of HIF-1α, c-Myc, and FOXO1 was quantified using quantitative real-time polymerase chain reaction (qPCR), and relative fold changes were analyzed by the 2^-ΔΔCt method. Results: Acidic conditions (pH 5.5–6.7) markedly upregulated HIF-1α and c-Myc while strongly suppressing FOXO1 expression. Conversely, mild alkalinity (pH 8.4) reversed this pattern, reducing HIF-1α and c-Myc while restoring FOXO1 expression, suggesting a transcriptional shift from glycolytic to oxidative metabolism. At higher alkalinity (pH 9.2), the expression of all three genes declined, indicating a threshold beyond which excessive pH elevation becomes detrimental to cellular regulation. Conclusion: Extracellular pH critically modulates metabolic gene expression in CRC cells. Acidic conditions activate glycolytic and oncogenic pathways via HIF-1α and c-Myc, while mild alkalinity suppresses these signals and reinstates tumor-suppressive FOXO1 activity. Controlled alkalinization of the TME may therefore represent a promising adjunctive approach to disrupt tumor metabolism and limit cancer progression.
Anticancer effectiveness of Artemisia annua ethanol extract against MDAMB-231 cancer cells Agustina, Rita; Ari, Psn Masruri Sulistiyanto; Sadikin, Nadya Audina N
International Journal of Cell and Biomedical Science Vol 4 No 10 (2025)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v4i10.68

Abstract

Background: Breast cancer remains one of the leading causes of cancer deaths worldwide, with triple-negative breast cancer (TNBC) posing a significant therapeutic challenge due to its lack of hormonal receptors and resistance to conventional treatment. Artemisia annua L., a medicinal plant traditionally used in Chinese medicine, has received attention for its diverse bioactive compounds, including flavonoids, phenolic acids, and sesquiterpene lactones, which exhibit potential anticancer properties. This study aims to evaluate the in vitro cytotoxic effect of A. annua ethanol extract against MDA-MB-231 human breast cancer cells using the MTT assay. Methods: Extracts were prepared in 10% DMSO and tested at concentrations ranging from 0 to 1000 µg/mL. MDA-MB-231 cells were seeded in 96-well plates and incubated for 24 h before treatment. Post-treatment, cell viability was assessed via MTT assay, and absorbance was measured at 595 nm. The percentage of cytotoxicity was calculated, and the IC₅₀ value was determined through linear regression analysis. Results: The results showed a clear cytotoxic response depending on the dose, with the extract achieving an IC₅₀ value of 56.83 µg·mL-¹ indicating a fairly strong correlation between concentration and cytotoxicity. These findings indicate that A. annua contains bioactive compounds that are able to inhibit cancer cell proliferation. Conclusion: In conclusion, Artemisia annua ethanol extract showed moderate cytotoxic activity against MDA-MB-231 cells, supporting its potential as a complementary therapeutic agent for TNBC. Further studies are needed to elucidate its molecular mechanisms and evaluate its efficacy in vivo.
Therapeutic Role of MSC-Secretome in Type 2 Diabetic Models: Correlation between Improved HOMA-IR and Attenuated Pancreatic-Hepatic Structural Alterations Wulandari, Putri Karenina Amalia; Sari, Fikriya Novita; Ardianto, Okky; Widyatmoko, Agus
International Journal of Cell and Biomedical Science Vol 4 No 10 (2025)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v4i10.69

Abstract

Background: Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance, β-cell dysfunction, and chronic hyperglycemia leading to multiorgan complications. Conventional therapies primarily target glycemic control but often fail to prevent progressive pancreatic and hepatic injury. This study investigated the therapeutic potential of hypoxic mesenchymal stem cell (MSC) secretome in improving insulin resistance and restoring tissue integrity in T2DM rat models. Methods: Male Wistar rats were induced with T2DM using a high-fat diet followed by streptozotocin–nicotinamide administration and subsequently treated intraperitoneally with MSC-secretome for four weeks. Fasting blood glucose, serum insulin levels, and HOMA-IR index were assessed, followed by histopathological evaluation of hepatic and pancreatic tissues. Results: The results showed that T2DM was significantly associated with elevated insulin levels and HOMA-IR values compared to the normal group, confirming insulin resistance. Treatment with MSC-secretome markedly reduced both parameters (p < 0.001), suggesting improved insulin sensitivity. Histological analyses revealed substantial hepatic and pancreatic degeneration in untreated diabetic rats, characterized by hepatocellular vacuolization, steatosis, and islet necrosis. Conclusion: Conversely, MSC-secretome treatment demonstrated remarkable restoration of lobular architecture, reduced lipid accumulation, and regeneration of pancreatic islets. These reparative effects are attributed to the secretome’s bioactive components that regulate oxidative stress, inflammation, and cellular regeneration. In conclusion, hypoxic MSC-secretome administration effectively ameliorates insulin resistance and attenuates hepatic and pancreatic damage in T2DM rats, underscoring its potential as a novel non-cell-based therapeutic strategy for metabolic disorders.

Page 5 of 6 | Total Record : 55

 2   3   4   5   6 

Filter by Year

2022 2025


Reset
Filter By Issues
All Issue Vol 4 No 11 (2025) Vol 4 No 10 (2025) Vol 3 No 9 (2024) Vol 3 No 8 (2024) Vol 3 No 7 (2024) Vol 2 No 6 (2023) Vol 2 No 5 (2023) Vol 2 No 4 (2023) Vol 1 No 3 (2022) Vol 1 No 2 (2022) Vol 1 No 1 (2022) More Issue